What is the global market size of N-Acetylcysteine Market?

N-Acetylcysteine Market size was valued at USD 1083.78 million in 2021 and is poised to grow from USD 1316.79 million in 2022 to USD 7598.08 million by 2030, growing at a CAGR of 21.5% in the forecast period (2023-2030).

N-Acetylcysteine Market Size, Share, Growth Analysis, By Type(Spray, Tracheal Drip, Tablet), By Application(Medicine, Nutritional Supplements, Others), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35I2290 | Region: Global | Published Date: July, 2001
Pages: 157 | Tables: 63 | Figures: 75

N-Acetylcysteine Market News

In April 2022, CMS I-neb® by Zambon received FDA Breakthrough Therapy Designation in Patients with Non-Cystic Fibrosis Bronchiectasis from Zambon (NCFB). CMS I-neb® is an experimental inhalation medication that is aimed to deliver precise concentrations of medicine directly to the site of illness while minimizing systemic exposure, which can cause toxicity and adverse effects.
In 2019, Zambon has finalised its transformative purchase of Breath Therapeutics, which is developing a treatment for the rare respiratory condition Bronchiolitis Obliterans Syndrome.

N-Acetylcysteine Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

N-Acetylcysteine Market size was valued at USD 1083.78 million in 2019 and is poised to grow from USD 1316.79 million in 2023 to USD 7598.08 million by 2031, growing at a CAGR of 21.5% in the forecast period (2024-2031).

The primary means through which the corporation competes in the market are innovation and commercial expansion. To compete, these businesses use a range of business methods, such as long-term supply agreements with several distribution channels. Major corporations have increasingly concentrated on entering Asian markets in recent years due to the availability of a target consumer base in the region. 'Zambon Company S.p.A.', 'Wuxi Jinghai Amino Acid Co., Ltd.', 'Pharma Nord ApS', 'Nacalai Tesque, Inc.', 'Manus Aktteva Biopharma LLP', 'Sigma-Aldrich Corporation', 'Taizhou Tianhong Biochemistry Technology Co., Ltd.', 'Alfa Aesar', 'Acetylcysteine China Inc.', 'Zhejiang Kangle Pharmaceutical Co., Ltd.', 'Wuhan Wuyao Pharmaceutical Co., Ltd.', 'Shijiazhuang Haitian Amino Acid Co., Ltd.', 'Jiangsu Gedi Biological Engineering Co., Ltd.', 'Nantong Baihua Bio-pharmaceutical Co., Ltd.', 'Changzhou Yabang-QH Pharmachem Co., Ltd.', 'Anhui Leafchem Co., Ltd.', 'Huahai Pharmaceutical Co., Ltd.', 'Hebei Guangren Pharmaceutical Technology Co., Ltd.', 'Sichuan Mingxin Pharmaceutical Co., Ltd.', 'Hangzhou Hyper Chemicals Limited'

N-acetyl cysteine is an antioxidant that may help prevent cancer. It is a medication used by doctors to treat acetaminophen (Tylenol) toxicity. It acts by binding the toxic forms of acetaminophen produced in the liver. N-acetyl cysteine is often used to treat coughs and other respiratory diseases. It is also claimed to treat the flu, dry eyes, and a variety of other illnesses, although there is no scientific evidence to back up many of these claims. There is also no convincing evidence to support the use of N-acetyl cysteine in the treatment of COVID-19.

NAC research is incredibly broad, spanning from cell-free systems to living organisms. On the one hand, there is the notion that administering NAC in the context of human illness can be helpful. Much research has been conducted to investigate the pharmacological application of NAC in animal illness models and clinical trials. Beyond its original applications as a mucolytic agent and an antidote to paracetamol overdose, subsequent research has looked into its possible utility in a variety of different pathophysiological settings, including mental and neurological illnesses, as well as coronavirus disease 2019.

North America is predicted to have the greatest market share due to considerable R&D in the medical industry. The business is booming as researchers work to find a treatment for HIV. Because of China's enormous manufacturing base, Asia Pacific is expected to develop significantly. The use of n-acetylcysteine for paracetamol intoxication is predicted to drive a significant increase in Europe. Eastern and southern Africa will account for over 52% of all HIV-infected persons by 2020. Because of the growing number of HIV patients, Latin America, the Middle East, and Africa will experience a significant increase by the end of the projection period.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

N-Acetylcysteine Market Size, Share, Growth Analysis, By Type(Spray, Tracheal Drip, Tablet), By Application(Medicine, Nutritional Supplements, Others), By Region - Industry Forecast 2025-2032

N-Acetylcysteine Market News

N-Acetylcysteine Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of N-Acetylcysteine Market?

Who are the key vendors in the N-Acetylcysteine Market?

What is the key driver of N-Acetylcysteine Market?

What is the key market trend for N-Acetylcysteine Market?

Which region accounted for the largest share in N-Acetylcysteine Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300